Panel discussion
KPMG AG
| Country: | Switzerland |
| Website: | www.home.kpmg.ch/ |
| Room: | Sydney |
| Date: | 03.05.2022 |
| Time: | 12:30-13:15 |
Panel title
How vital is ESG reporting for biotech companies and their investors?
Panel summary
The majority of pre-commercial biotech companies do not have ESG public disclosures. There is also no consensus on reporting standards for small biotech companies. At the same time, surveys show that nearly all biotech executives and investors expect ESG to grow in importance in the coming years. The panelist will discuss the topic(s) on ESG disclosure from the points of view of a biotech company, of an ESG expert, and of an investor.
Speaker information
Moderation
Monika Jones
Panelists
- Andreas Emmenegger, Chief Financial Officer, Molecular Partners AG
- Silvan Jurt, Partner / Head Corporate Sustainability Services
- Markus Peter, Head Investments and Products, Bellevue Asset Management AG
- Funding organization : TBC
Company profile
KPMG is a leading professional services firm in Switzerland. Through its strong regional presence KPMG is close to you, helping you navigate today’s turbulences to find tomorrow’s answers. In audit, tax and advisory, KPMG is noted for clear and consistent solutions. KPMGs life sciences experts have a deep understanding of the industry to support companies in challenges around cost & efficiency, valuation & financing or regulatory compliance.
